RELPI
4.1.2022 15:02:06 CET | Business Wire | Press release
The Real Estate Limited Partner Institute (RELPI) today announced the expansion of its compelling Interests Aligned programs to Europe and the United Kingdom with the appointment of institutional real estate investment and media professional Arno Van Grondelle as CEO of RELPI Europe.
RELPI’s intimate, focused and curated local meet-ups foster open conversation and deep relationships among leading stakeholders in the investment and allocation of capital in real estate. The series was formally launched in 2021 with events in Austin, New York and Philadelphia, and was met with an overwhelming interest and attendance. In addition to the expansion into Europe and the United Kingdom, RELPI has announced events in Chicago, Cleveland, Los Angeles, San Francisco and New York so far in 2022.
“Our success and expansion reflect the pent-up demand for in-person gatherings and virtual meetings of informed, high-level executives to share insights, ideas and transparent conversations devoted to best practices in institutional real estate asset allocation and investment,” said RELPI’s CEO and Executive Director Jonathan Schein. “In less than six months, the RELPI community has grown to include more than 125 pension funds, endowments foundations and family offices, as well as more than 50 fund managers.”
The addition of Arno Van Grondelle as CEO of RELPI Europe will accelerate this expansion. Mr. Van Grondelle brings extensive knowledge and leadership experience from his many years working in the institutional real estate investment and media industries. Most recently he served as Managing Director of Europe at Institutional Real Estate Inc., responsible for client relations, business development and sales for Institutional Real Estate Europe magazine. He previously served as International Sales Director at PropertyEU, where he was responsible for the sales of PropertyEU's comprehensive media portfolio, including PropertyEU magazine and EXPO Real's Preview and Daily News.
"Arno’s wealth of knowledge, experience and relationships in the European investor and LP arena will solidify RELPI’s fast mover status in the industry,” said Mr. Schein "His professionalism and market acumen will make a great addition to our growing platform designed to connect key players for the mutual benefit of the dynamic private equity real estate investment and capital industries.”
“I am very excited to join RELPI and further build this community in Europe,” said Mr. Van Grondelle. “We are dedicated to bringing together real estate institutional investors, fund managers, operating companies and those organizations allied to the industry on a local, regional and global scale.”
The Interests Aligned series are designed to be streamlined and efficient (just three hours long) with a strong emphasis on social networking, offering RELPI’s unique value proposition – intimate, ultrahigh-value gatherings, in a streamlined, economically effective manner, with “proximity” in mind.
For more information about the Interests Aligned series, to register or inquire about membership, please visit: www.RELPI.org
About RELPI
As an established producer of successful meetings, events and conferences devoted to the global institutional investment community for the commercial real estate class, with “proximity” as the prime value proposition, RELPI is perfectly positioned to deliver a best-of-both-worlds solution: intimate, ultrahigh-value gatherings in a streamlined, economically effective way. From “virtual salons” and global summits focused on investors in all major global markets, to emerging manager programs and even “private label,” bespoke roundtables, RELPI is enabling tomorrow’s business connectivity today.
https://www.relpi.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005129/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom